Lineage Cell Therapeutics Inc (LCTX)

[terry hallinan]

BTX is not just a pretty face.

BioTime to Participate in Upcoming Conferences

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that its management will participate in the following conferences:

Torrey Hills Capital Emerging Growth Conference on Tuesday, November 14, 2017. This conference is being held at the Morgan Run Club and Resort in Rancho Santa Fe, CA.

LD Micro 10th Annual Main Event Conference on Wednesday, December 6, 2017. This conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

At each conference mentioned above the Company will be hosting one-on-one and group meetings throughout the day. Analysts and portfolio managers that wish to attend the conference or would like to request a meeting should contact Torrey Hills Capital or LD Micro.

About BioTime

BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell and drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells, which can become any type of cell in the human body, and cell/drug delivery. Renevia®, a cell delivery product, met its primary endpoint in an EU pivotal clinical trial for the treatment of facial lipoatrophy in HIV patients earlier this year. Submission for approval of Renevia® in the EU is expected to be early 2018, with possible approval and commercial launch in 2018. There were no device related serious adverse events reported. OpRegen®, a retinal pigment epithelium transplant therapy, is in a Phase I/IIa multicenter trial for the treatment of dry age-related macular degeneration, the leading cause of blindness in developing countries. There were no related serious adverse events reported. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, AgeX Therapeutics, Inc.

http://tinyurl.com/y9u2svjg

My apologies to most any stockholder or prospective stockholder for reposting somewhat voluminous information on BTX's numerous lines of business but presume these are precisely what serial entrepreneur Michael West is selling at these conferences in looking to partner or even possibly sell various lines of business.

While other development-stage biotechs are struggling mightily for just a small place in the sun for its narrow slice of science, BTX is sprouting wings, growing cash and delivering babies like rabbits.

Whatever the eventual outcome, this is a genuine masterpiece of entrepreneurship that sludgy, over the hill, giant pharmaceuticals love to brag about as they become increasingly obsolescent.

JMO.

Best, Terry